Walder Wyss officialised the promotion of Iliana Djagova (pictured right) to partner in the corporate and M&A team, and Matthias Lötscher (pictured left) to counsel in the banking & finance team, both
Search Results for: walder wyss
Walder Wyss advised Allegria Therapeutics, a Basel-based biotech company developing therapies for mast cell-mediated diseases, throughout its USD 5.1 million seed extension funding round. The context ALK Abelló led the round in question, with support from
Antin Infrastructure Partners — a private equity firm with a focus on infrastructure — agreed to acquire NorthC, an enterprise colocation data center platform in Northwest Europe. In connection with the deal, which is expected to close
Advestra advised Galderma throughout its issuance of CHF 175 million bonds due 2030 with a coupon of 0.9425%. In connection with the transaction, Walder Wyss represented the banking syndicate, including joint lead managers BNP Paribas and UBS. The
Walder Wyss advised SIX-listed positioning and wireless communication technologies specialist u-blox Holding as ZI Zenith – a European indirect subsidiary owned by investment funds managed or advised by Advent International – has completed its public tender offer
Walder Wyss advised Distalmotion, a globally active MedTech company based in Lausanne, throughout closing of its USD 150 million series G financing round. Revival Healthcare Capital led the funding round in question, with support from inside
Sedrun Solar – a project for a large-scale alpine photovoltaic plant in Switzerland – secured a syndicated project financing led by Zürcher Kantonalbank. In connection with the operation, Bratschi advised Sedrun Solar, while Walder Wyss represented
Bluu Unit – a portfolio company of Triton Smaller Mid-Cap Fund II active as a provider of sustainable refrigeration, air conditioning and heating technologies – completed the acquisition of IPS Gebäudetechnik, a specialist in the same
Globally active biopharmaceutical company AstraZeneca has exercised an option to acquire obesity drug startup SixPeaks Bio. In connection with the deal, Lenz & Staehelin represented AstraZeneca, while Walder Wyss advised SixPeaks Bio and its shareholders.
Welcome to our weekly newsletter: Signed, Sealed, Weekend. · Nexthink, a DEX management specialist backed by Permira, Highland, Index and Auriga, signed a definitive agreement to receive a majority investment from globally active tech investor Vista
